@inproceedings{inproceedings, title  = {{A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC)}},

 url = {{}},

 year = {{2023}},

 month = {{1}},

 author = {{Guo C and Crabb SJ and Pacey S and Coyle V and Danson S and Villacampa G and Chandran K and Paschalis A and Riisnaes R and Ferreira A and Carreira S et al}},

 volume = {{41}},

 journal = {{JOURNAL OF CLINICAL ONCOLOGY}},

 issue = {{16}},

 note = {{Accessed on 2025/01/03}}}